TRICIA GILLIGAN: Open Payments
NPI 1306819750 · HUTCHINSON, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$972 in 50 payments from 14 companies in 2025. Trend: 2023 $898 · 2024 $2,496 · 2025 $972
Food & beverage: $972
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 12 | $222 |
| GENZYME CORPORATION | 8 | $162 |
| AstraZeneca Pharmaceuticals LP | 7 | $126 |
| Verona Pharma, Inc. | 5 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Grifols USA, LLC | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Genentech USA, Inc. | 2 | $52 |
| Viatris Specialty LLC | 2 | $36 |
| Amgen Inc. | 2 | $32 |
Products named: DUPIXENT, TRELEGY ELLIPTA, NUCALA, Ohtuvayre, GLASSIA, Prolastin-C Liquid, Xolair, AIRSUPRA.
Industry payments across KS — which companies pay providers there.
